Targeted therapy has become the most promising area of drug development in advanced colorectal cancer. Currently, bevacizumab is added as standard treatment to fluoropyrimidine containing first line chemotherapy. The optimal duration of treatment with chemotherapy in patients with advanced colorectal cancer has not been defined, and the use of targeted agents adds further questions to this issue. The CAIRO3 study was the first study in which the role of maintenance treatment with low-dose capecitabine plus bevacizumab was investigated. Principal investigators are C.J.A. Punt and M. Koopman, translational research was conducted in collaboration with J.H.J.M. van Krieken (UMC St Radboud).
Previously untreated patients with advanced colorectal cancer with stable disease or better after induction therapy with 6 cycles of capecitabine, oxaliplatin, and bevacizumab are randomised between observation and maintenance treatment with low-dose capecitabine and bevacizumab. Upon progression (PFS1), patients in both arms were treated with the initial MTD regimen of oxaliplatin, capecitabine, and bevacizumab until progression (PFS2). Accrual was completed in March 2008 and 96 patients were randomised.
p/a UMC St Radboud
6500 HB Nijmegen
More information about this trial is available at our members only page.